KR100748010B1 - 매트릭스 메탈로프로테이나제의 역 하이드록사메이트 억제제 - Google Patents

매트릭스 메탈로프로테이나제의 역 하이드록사메이트 억제제 Download PDF

Info

Publication number
KR100748010B1
KR100748010B1 KR1020017009393A KR20017009393A KR100748010B1 KR 100748010 B1 KR100748010 B1 KR 100748010B1 KR 1020017009393 A KR1020017009393 A KR 1020017009393A KR 20017009393 A KR20017009393 A KR 20017009393A KR 100748010 B1 KR100748010 B1 KR 100748010B1
Authority
KR
South Korea
Prior art keywords
phenyl
hydroxy
ethyl
sulfonyl
phenoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020017009393A
Other languages
English (en)
Korean (ko)
Other versions
KR20010101709A (ko
Inventor
커틴마이클엘.
다이위자
데이빗슨스티븐케이.
헤이맨하워드알.
홈즈제임스에이치.
마이클라이즈마이클알.
스타인맨더글라스에이치.
Original Assignee
아보트 러보러터리즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아보트 러보러터리즈 filed Critical 아보트 러보러터리즈
Publication of KR20010101709A publication Critical patent/KR20010101709A/ko
Application granted granted Critical
Publication of KR100748010B1 publication Critical patent/KR100748010B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020017009393A 1999-01-27 2000-01-27 매트릭스 메탈로프로테이나제의 역 하이드록사메이트 억제제 Expired - Fee Related KR100748010B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23908799A 1999-01-27 1999-01-27
US09/239,087 1999-01-27

Publications (2)

Publication Number Publication Date
KR20010101709A KR20010101709A (ko) 2001-11-14
KR100748010B1 true KR100748010B1 (ko) 2007-08-09

Family

ID=22900549

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017009393A Expired - Fee Related KR100748010B1 (ko) 1999-01-27 2000-01-27 매트릭스 메탈로프로테이나제의 역 하이드록사메이트 억제제

Country Status (28)

Country Link
US (1) US20020007060A1 (enExample)
EP (1) EP1147101B1 (enExample)
JP (1) JP4718686B2 (enExample)
KR (1) KR100748010B1 (enExample)
CN (1) CN1222519C (enExample)
AR (1) AR029329A1 (enExample)
AT (1) ATE228122T1 (enExample)
AU (1) AU764383B2 (enExample)
BG (1) BG105782A (enExample)
BR (1) BR0007278A (enExample)
CA (1) CA2358951C (enExample)
CO (1) CO5150194A1 (enExample)
CZ (1) CZ20012591A3 (enExample)
DE (1) DE60000819T2 (enExample)
DK (1) DK1147101T3 (enExample)
ES (1) ES2187443T3 (enExample)
HK (1) HK1043115A1 (enExample)
HU (1) HUP0105477A2 (enExample)
IL (1) IL143713A0 (enExample)
NO (1) NO20013669L (enExample)
NZ (1) NZ512372A (enExample)
PL (1) PL349771A1 (enExample)
PT (1) PT1147101E (enExample)
SK (1) SK10582001A3 (enExample)
TR (1) TR200102159T2 (enExample)
TW (1) TWI225486B (enExample)
WO (1) WO2000044739A1 (enExample)
ZA (1) ZA200104979B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AU2001298065A1 (en) * 2001-01-12 2003-09-02 Abbott Laboratories Process for the preparation of matrix metalloproteinase inhibitors
EP1431285B1 (en) 2001-09-07 2009-01-07 Kaken Pharmaceutical Co., Ltd. Reverse hydroxamic acid derivatives
EP1896404B1 (en) * 2005-06-27 2014-09-17 Nabriva Therapeutics AG Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group
US20110015158A1 (en) 2007-12-11 2011-01-20 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
WO2015107139A1 (en) 2014-01-17 2015-07-23 Proyecto De Biomedicina Cima, S.L. Compounds for use as antifibrinolytic agents

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780386A1 (en) * 1995-12-20 1997-06-25 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0780386A1 (en) * 1995-12-20 1997-06-25 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors

Also Published As

Publication number Publication date
CA2358951A1 (en) 2000-08-03
AU2739100A (en) 2000-08-18
HK1043115A1 (zh) 2002-09-06
JP2002535398A (ja) 2002-10-22
IL143713A0 (en) 2002-04-21
HUP0105477A2 (hu) 2002-05-29
TR200102159T2 (tr) 2001-12-21
BG105782A (en) 2002-04-30
US20020007060A1 (en) 2002-01-17
SK10582001A3 (sk) 2001-12-03
AR029329A1 (es) 2003-06-25
NO20013669D0 (no) 2001-07-26
EP1147101A1 (en) 2001-10-24
WO2000044739A1 (en) 2000-08-03
PL349771A1 (en) 2002-09-09
NZ512372A (en) 2003-01-31
TWI225486B (en) 2004-12-21
ATE228122T1 (de) 2002-12-15
CN1339032A (zh) 2002-03-06
BR0007278A (pt) 2001-11-27
ZA200104979B (en) 2002-09-18
NO20013669L (no) 2001-09-27
EP1147101B1 (en) 2002-11-20
DE60000819D1 (de) 2003-01-02
CZ20012591A3 (cs) 2001-12-12
DE60000819T2 (de) 2003-09-04
CO5150194A1 (es) 2002-04-29
PT1147101E (pt) 2003-04-30
DK1147101T3 (da) 2003-03-10
AU764383B2 (en) 2003-08-14
CA2358951C (en) 2009-10-20
KR20010101709A (ko) 2001-11-14
CN1222519C (zh) 2005-10-12
ES2187443T3 (es) 2003-06-16
JP4718686B2 (ja) 2011-07-06

Similar Documents

Publication Publication Date Title
JP3662941B2 (ja) マトリックスメタロプロテイナーゼのリバースヒドロキサメート阻害剤
US6235786B1 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
JP4199309B2 (ja) 新規アセトアミド誘導体およびプロテアーゼ阻害
US6294573B1 (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
ES2298761T3 (es) Acidos de biariloximetilarenocarboxilicos.
KR20110110286A (ko) Ｎ-아실 안트라닐산 유도체 또는 그 염
EA019385B1 (ru) ЗАМЕЩЕННЫЕ ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ РТРазы
SK174899A3 (en) Urokinase inhibitors
KR100748010B1 (ko) 매트릭스 메탈로프로테이나제의 역 하이드록사메이트 억제제
US5418230A (en) Benzylidene derivatives
BG107908A (bg) Инхибитори на фарнезилтрансфераза
IL173305A (en) Matrix metalloproteinase inhibitors, their use in preparation of medicaments, pharmaceutical compositions comprising them and methods of preparation thereof
WO2000044712A1 (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases
MXPA01007658A (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
JP2005537216A (ja) セリンおよびシステインプロテアーゼの阻害剤としてのプロピルカーバメート誘導体
US20020128496A1 (en) Process for the preparation of matrix metalloproteinase inhibitors
HUP9903675A2 (hu) Új acetamid-származékok és proteáz inhibitorok
MXPA99011694A (en) Reverse hydroxamate inhibitors of matrix metalloproteinases
CZ473099A3 (cs) Reversní hydroxamátové inhibitory matrixových metalloproteinás
HK1028023B (en) N-hydroxyformamide derivatives as inhibitors of matrix metalloproteinases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20100729

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110804

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110804

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000